The role of CREBBP/EP300 and its therapeutic implications in hematological malignancies

Y Zhu, Z Wang, Y Li, H Peng, J Liu, J Zhang, X **ao - Cancers, 2023 - mdpi.com
Simple Summary Through their regulatory effects on gene expression, histone
acetyltransferases have been implicated in the normal physiological activities and genesis …

Extracellular vesicles from red blood cells and their evolving roles in health, coagulopathy and therapy

K Thangaraju, SN Neerukonda, U Katneni… - International journal of …, 2020 - mdpi.com
Red blood cells (RBCs) release extracellular vesicles (EVs) including both endosome-
derived exosomes and plasma-membrane-derived microvesicles (MVs). RBC-derived EVs …

Multiple myeloma: The (r) evolution of current therapy and a glance into the future

KC Anderson - Haematologica, 2020 - pmc.ncbi.nlm.nih.gov
Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …

The multiple roles of interferon regulatory factor family in health and disease

L Wang, Y Zhu, N Zhang, Y **an, Y Tang, J Ye… - … and Targeted Therapy, 2024 - nature.com
Abstract Interferon Regulatory Factors (IRFs), a family of transcription factors, profoundly
influence the immune system, impacting both physiological and pathological processes …

Decoding the role of miRNAs in multiple myeloma pathogenesis: a focus on signaling pathways

AM Yehia, EGE Elsakka, AI Abulsoud… - … -Research and Practice, 2023 - Elsevier
Multiple myeloma (MM) is a cancer of plasma cells that has been extensively studied in
recent years, with researchers increasingly focusing on the role of microRNAs (miRNAs) in …

Direct inhibition of IRF-dependent transcriptional regulatory mechanisms associated with disease

A Antonczyk, B Krist, M Sajek, A Michalska… - Frontiers in …, 2019 - frontiersin.org
Interferon regulatory factors (IRFs) are a family of homologous proteins that regulate the
transcription of interferons (IFNs) and IFN-induced gene expression. As such they are …

Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

AM Poos, N Prokoph, MJ Przybilla, JP Mallm, S Steiger… - Blood, 2023 - ashpublications.org
Intratumor heterogeneity as a clinical challenge becomes most evident after several
treatment lines, when multidrug-resistant subclones accumulate. To address this challenge …

Roles of miRNA dysregulation in the pathogenesis of multiple myeloma

D Chen, X Yang, M Liu, Z Zhang, E **ng - Cancer gene therapy, 2021 - nature.com
Multiple myeloma (MM) is a malignant disease of plasma cells with complex pathology,
causing significant morbidity due to its end-organ destruction. The outcomes of patients with …

miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1

S Hua, Y Quan, M Zhan, H Liao, Y Li, L Lu - Cancer Cell International, 2019 - Springer
Abstract Background Thioredoxin reductase 1 (TXNRD1) is an antioxidant enzyme
reportedly overexpressed in hepatocellular carcinoma (HCC); however, the detailed function …

A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells

A Gullà, MT Di Martino, ME Gallo Cantafio… - Clinical cancer …, 2016 - aacrjournals.org
Purpose: The onset of drug resistance is a major cause of treatment failure in multiple
myeloma. Although increasing evidence is defining the role of miRNAs in mediating drug …